Dilated CardiomyopathyNCT02001961
Pathophysiology of Dilated Cardiomyopathy
An observational study of Dilated Cardiomyopathy, run by Great Ormond Street Hospital for Children NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This will be a cross-sectional, observational study. Null hypothesis: There is no difference in the amount of extracellular volume (ECV or scarring) in the hearts of patients with heart failure as compared to control subjects. Heart failure occurs when the heart muscle has become too weak to work properly. Read more about this study
- Who is it for?
- Ages Up to 16 yearsHealthy volunteers can take part
- Conditions the study is for
- Dilated Cardiomyopathy
- How many people
- 0 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 2014to Jun 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 16 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: 1. Heart Failure Patients (MRI Clinically indicated) 2. Heart Failure Patients (Voluntarily recruited from clinic) 1. 8-16 years of age 2. Non-GA only 3. Control subjects (Clinically indicated brain MRI with contrast)
Who may be able to join
- Established diagnosis of DCM for 3 months
- Ability to cooperate with MRI scan without general anaesthesia (volunteers over 8 years), or any age if cardiac MRi clinically indicated
- Provides written, informed consent
Who cannot join
- Patient exclusion criteria:
- Estimated GFR <30mls/min
- Contraindication to MRI (see appendix 1)
- Chronic inflammation/ malignancy/ connective tissue disease
- Structural congenital heart disease/ previous cardiac surgery
- Control Group Exclusion Criteria:
Show all 19Show fewer
- History of heart failure or congenital heart disease
- Contraindication to MRI (see below)
- Chronic inflammation/ malignancy/ connective tissue disease
- Previous malignancy
- Central nervous system aneurysm clips
- Implanted neural stimulator
- Implanted cardiac pacemaker or defibrillator
- Cochlear implant
- Ocular foreign body e.g. metal shavings
- Other implanted medical devices e.g. drug infusion ports
- Insulin pump
- Metal shrapnel or bullet
- Pregnant women (patients who are uncertain will be required to have a urinary or blood screening test)
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Great Ormond Street Hospital NHS Trust
London, WC1N 3JH
About this study
Official title: Using Novel Blood and Imaging Biomarkers to Better Understand the Pathophysiology of Paediatric Dilated Cardiomyopathy
This will be a cross-sectional, observational study.
Null hypothesis:
Read more
There is no difference in the amount of extracellular volume (ECV or scarring) in the hearts of patients with heart failure as compared to control subjects.
Heart failure occurs when the heart muscle has become too weak to work properly. It is associated with an increase in the amount of connective tissue (collagen) which replaces dead heart muscle cells (scarring). Currently a biopsy of the muscle is the only way to measure the amount of scarring. This is invasive and rarely done in children. Because of this, it is difficult to measure the amount of scarring in a particular patient or disease process, which is important for improving our understanding and treatment of the disease.
Cardiac magnetic resonance imaging (MRI) is a non-invasive imaging tool which is routinely used to look at areas of local scarring in heart muscle. Because the scarring is so widespread in paediatric patients, we have not been able to use this method previously. Now new imaging techniques allow us to look at widespread scarring but these have not yet been validated in children.
We plan to use late gadolinium enhancement (T1 mapping) to measure the amount of scarring in patients with heart failure (we have evidence that their heart biopsies show increased amounts of scar tissue) and children having MRI scans for other reasons. We will use measures of function including echocardiography and 6 minute walk test to compare to the amount of scarring. This will help us to know whether the amount of scarring will be clinically useful.
We will look at the amount of various proteins in the blood of patients and control subjects which are related to the scarring and cell death processes. We already use blood tests to monitor heart failure and these tests may help us to refine our testing and improve timing of treatment (e.g. transplantation).
This study will help us to design further research in this field.
Read the detailed description
All patients will be under the care of Great Ormond Street Hospital.
Patient Groups:
There will be three main patient groups:
- Heart Failure Patients (MRI Clinically indicated)
- Heart Failure Patients (Voluntarily recruited from clinic)
- 8-16 years of age
- Non-GA only
- Control subjects (Clinically indicated brain MRI with contrast)
Patient recruitment
We will include Great Ormond Street patients in this trial who are known to the heart failure team because they have been diagnosed with DCM for at least 3 months. They will have an established diagnosis of heart failure and will be under regular follow up. Where possible, we will attempt to align the research study review date with that of the patient's regular annual review.
We will include patients who are to have a cardiac MRI scan with contrast for clinical reasons. These patients will be of any age and will have the scan under GA if appropriate, In addition, we will recruit patients from heart failure clinic who are not due to have scans for clinical reasons. These patients will be between 8-16 years to allow cooperation with the MRI scan protocol without the need for general anaesthetic (GA).
Age-matched control patients will be those having routine MRI with contrast for non-cardiac MRI scans. They will also have blood tests for cardiac biomarkers at the time of insertion of the cannula for contrast injection. These will be patients identified as requiring gadolinium contrast for neurological imaging. They will include patients who are awake and those sedated or under GA. These patients will mainly be having routine brain MRI with contrast for epilepsy.
Both groups will be fully consented.
Heart Failure Patients:
We will recruit patients being referred for cardiac MRI scanning for clinical reasons as well as inviting patients to volunteer for an MRI. Patients who do not require a cardiac MRI for clinical reasons will be over the age of 8 years to allow for cooperation with the MRI without general anaesthesia. Patients under follow up by the heart failure team will be contacted by their primary care consultant in the first instance to introduce the study and invite the patient to participate. It will be made clear there is no obligation to join the study and their treatment will be unaffected by their decision. They will be free to withdraw consent at any time. The patients will be invited to phone the study coordinator (DP) to ask questions, express willingness to participate or to decline. Non-responders will be sent one further letter of invitation.
Control subjects:
Patients being referred to the MRI department at Great Ormond Street Hospital will be identified once they have been allocated to a neurological MRI protocol with gadolinium enhancement. The radiologist allocating the patient will contact the patients' primary consultant to inform them about the study and request permission to contact the family. The family will be contacted once permission has been given, first by phone and then information sheets will be provided. The patients will be invited to phone the study coordinator (DP) to ask questions, express willingness to participate or to decline. Non-responders will be sent one further letter of invitation.
Travel costs will be reimbursed where these are incurred specifically for participation in the study.
Consent:
Written, informed consent will be obtained from all participants if they choose to take part in this study. Information sheets will also be provided to the patients' GP and their cardiology physician, if they are under separate cardiology follow-up. Patients will be free to withdraw at any time.
Risks \& Burdens from the study protocol
The main risk arising from our study relates to the insertion of an IV line and administration of a gadolinium-based contrast agent. Such contrast agents are widely used in clinical practice and are extremely safe when administered within standard dosage guidelines. There are, however, potential complications of allergic reaction and development of Nephrogenic Systemic Fibrosis (NSF). Such allergic reactions are rare and when they occur, the majority are mild.
To mitigate this risk we will exclude patients with a previous history of allergic response to gadolinium-containing agents as well as those with a severe atopic history or history of renal impairment. There are no known cases of NSF in patients with normal renal function(1). We will measure renal function in all patients within 1 month of the study.
For patients being scanned specifically for the study, we will select patients over 8 years of age, to avoid the need for general anaesthetic. We will attempt to select mainly patients who require MRI scanning with contrast for clinical indications. The control group will only consist of those having MRI for clinical indications. In this case, the only burden will be increased time in the scanner of around 20 minutes to obtain the sequences required. Evidence from our institution shows that the increased duration of general anaesthetic is not harmful and does not lead to complications or adverse events.
We will obtain blood samples for serum bio-marker measurement and haematocrit at the time of IV line insertion so this does not represent an additional intervention for the patient. We will use local anaesthetic cream or spray as requested by the patient and will use play and distraction techniques to minimise distress.
There are no potential adverse effects of a properly conducted transthoracic echocardiogram.
The 6 minute walk test will only be employed if the patient is able and willing to participate.
There are no potential adverse effects of a properly conducted MRI scan. The magnetic field and RF pulses are not known to cause any physical harm in properly selected subjects. Such selection will involve careful screening of the patients' medical history for any surgery or accidents that might have introduced metal to their bodies e.g. cerebral artery aneurysm clips or a metal foreign body in an eye. This will require a review of the patient's notes once consent has been given and a written checklist at the time of MRI scan. Such patients are not scanned in standard clinical practice and would also be excluded from the study.
Therefore, there is no realistic potential for pain, discomfort, distress, inconvenience or detrimental change to lifestyle anticipated for the participants from the MRI scan itself.
- Dillman, J.R., J.H. Ellis, R.H. Cohan, P.J. Strouse, and S.C. Jan, Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol, 2007. 189(6): p. 1533-8.
Unexpected clinical findings
If new abnormalities or medical issues come to light as a result of the study investigations, the patient's GP and hospital consultant will be informed. Medical follow-up of these issues will be through the patient's usual medical carers.
- Conditions
- Dilated Cardiomyopathy
- Keywords
- Fibrosis, collagen metabolism, paediatric, dilated cardiomyopathy, biomarkers, T1 mapping, MRI
- Medical subject headings
- Cardiomyopathy, Dilated, Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Heart failure | Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years. | |
| Control | Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fibrosis
Higher fibrosis score (ECV) in heart failure patients in comparison to control subjects
Measured: 6 months
Secondary outcomes (2)
Biomarkers
Significantly different pattern of blood biomarkers in heart failure patients as compared to control subjects
Measured: 6 months
Disease Severity
Significant correlation between fibrosis score on MRI or biomarker profile and clinical parameters (including 6 minute walk test and disease severity).
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2013 (estimated)
- Study startJan 2014 (estimated)
- Primary completionJun 2014 (estimated)
- Study completionJun 2015 (estimated)
Why it stopped: Study was withdrawn prior to R\&D approval
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dilated CardiomyopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael Burch, MD, Study director, Great Ormond Street Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02001961
- Sponsor's protocol ID
- 12CC23
- Status last verified
- Jan 2022
- First submitted
- 29 Nov 2013
- Last updated
- 20 Jan 2022
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using Novel Blood and Imaging Biomarkers to Better Understand the Pathophysiology of Paediatric Dilated Cardiomyopathy
- ClinicalTrials.gov ID
- NCT02001961
- Acronym / sponsor ID
- 12CC23
- Conditions
- Dilated Cardiomyopathy
- Keywords
- Fibrosis, collagen metabolism, paediatric, dilated cardiomyopathy, biomarkers, T1 mapping, MRI
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Study was withdrawn prior to R\&D approval
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Great Ormond Street Hospital for Children NHS Foundation TrustUniversity, hospital or other
- Study start
- Jan 2014 (estimated)
- Primary completion
- Jun 2014 (estimated)
- Study completion
- Jun 2015 (estimated)
- First posted
- 5 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This will be a cross-sectional, observational study.
Null hypothesis:
There is no difference in the amount of extracellular volume (ECV or scarring) in the hearts of patients with heart failure as compared to control subjects.
Heart failure occurs when the heart muscle has become too weak to work properly. It is associated with an increase in the amount of connective tissue (collagen) which replaces dead heart muscle cells (scarring). Currently a biopsy of the muscle is the only way to measure the amount of scarring. This is invasive and rarely done in children. Because of this, it is difficult to measure the amount of scarring in a particular patient or disease process, which is important for improving our understanding and treatment of the disease.
Cardiac magnetic resonance imaging (MRI) is a non-invasive imaging tool which is routinely used to look at areas of local scarring in heart muscle. Because the scarring is so widespread in paediatric patients, we have not been able to use this method previously. Now new imaging techniques allow us to look at widespread scarring but these have not yet been validated in children.
We plan to use late gadolinium enhancement (T1 mapping) to measure the amount of scarring in patients with heart failure (we have evidence that their heart biopsies show increased amounts of scar tissue) and children having MRI scans for other reasons. We will use measures of function including echocardiography and 6 minute walk test to compare to the amount of scarring. This will help us to know whether the amount of scarring will be clinically useful.
We will look at the amount of various proteins in the blood of patients and control subjects which are related to the scarring and cell death processes. We already use blood tests to monitor heart failure and these tests may help us to refine our testing and improve timing of treatment (e.g. transplantation).
This study will help us to design further research in this field.
Detailed description
All patients will be under the care of Great Ormond Street Hospital.
Patient Groups:
There will be three main patient groups:
- Heart Failure Patients (MRI Clinically indicated)
- Heart Failure Patients (Voluntarily recruited from clinic)
- 8-16 years of age
- Non-GA only
- Control subjects (Clinically indicated brain MRI with contrast)
Patient recruitment
We will include Great Ormond Street patients in this trial who are known to the heart failure team because they have been diagnosed with DCM for at least 3 months. They will have an established diagnosis of heart failure and will be under regular follow up. Where possible, we will attempt to align the research study review date with that of the patient's regular annual review.
We will include patients who are to have a cardiac MRI scan with contrast for clinical reasons. These patients will be of any age and will have the scan under GA if appropriate, In addition, we will recruit patients from heart failure clinic who are not due to have scans for clinical reasons. These patients will be between 8-16 years to allow cooperation with the MRI scan protocol without the need for general anaesthetic (GA).
Age-matched control patients will be those having routine MRI with contrast for non-cardiac MRI scans. They will also have blood tests for cardiac biomarkers at the time of insertion of the cannula for contrast injection. These will be patients identified as requiring gadolinium contrast for neurological imaging. They will include patients who are awake and those sedated or under GA. These patients will mainly be having routine brain MRI with contrast for epilepsy.
Both groups will be fully consented.
Heart Failure Patients:
We will recruit patients being referred for cardiac MRI scanning for clinical reasons as well as inviting patients to volunteer for an MRI. Patients who do not require a cardiac MRI for clinical reasons will be over the age of 8 years to allow for cooperation with the MRI without general anaesthesia. Patients under follow up by the heart failure team will be contacted by their primary care consultant in the first instance to introduce the study and invite the patient to participate. It will be made clear there is no obligation to join the study and their treatment will be unaffected by their decision. They will be free to withdraw consent at any time. The patients will be invited to phone the study coordinator (DP) to ask questions, express willingness to participate or to decline. Non-responders will be sent one further letter of invitation.
Control subjects:
Patients being referred to the MRI department at Great Ormond Street Hospital will be identified once they have been allocated to a neurological MRI protocol with gadolinium enhancement. The radiologist allocating the patient will contact the patients' primary consultant to inform them about the study and request permission to contact the family. The family will be contacted once permission has been given, first by phone and then information sheets will be provided. The patients will be invited to phone the study coordinator (DP) to ask questions, express willingness to participate or to decline. Non-responders will be sent one further letter of invitation.
Travel costs will be reimbursed where these are incurred specifically for participation in the study.
Consent:
Written, informed consent will be obtained from all participants if they choose to take part in this study. Information sheets will also be provided to the patients' GP and their cardiology physician, if they are under separate cardiology follow-up. Patients will be free to withdraw at any time.
Risks \& Burdens from the study protocol
The main risk arising from our study relates to the insertion of an IV line and administration of a gadolinium-based contrast agent. Such contrast agents are widely used in clinical practice and are extremely safe when administered within standard dosage guidelines. There are, however, potential complications of allergic reaction and development of Nephrogenic Systemic Fibrosis (NSF). Such allergic reactions are rare and when they occur, the majority are mild.
To mitigate this risk we will exclude patients with a previous history of allergic response to gadolinium-containing agents as well as those with a severe atopic history or history of renal impairment. There are no known cases of NSF in patients with normal renal function(1). We will measure renal function in all patients within 1 month of the study.
For patients being scanned specifically for the study, we will select patients over 8 years of age, to avoid the need for general anaesthetic. We will attempt to select mainly patients who require MRI scanning with contrast for clinical indications. The control group will only consist of those having MRI for clinical indications. In this case, the only burden will be increased time in the scanner of around 20 minutes to obtain the sequences required. Evidence from our institution shows that the increased duration of general anaesthetic is not harmful and does not lead to complications or adverse events.
We will obtain blood samples for serum bio-marker measurement and haematocrit at the time of IV line insertion so this does not represent an additional intervention for the patient. We will use local anaesthetic cream or spray as requested by the patient and will use play and distraction techniques to minimise distress.
There are no potential adverse effects of a properly conducted transthoracic echocardiogram.
The 6 minute walk test will only be employed if the patient is able and willing to participate.
There are no potential adverse effects of a properly conducted MRI scan. The magnetic field and RF pulses are not known to cause any physical harm in properly selected subjects. Such selection will involve careful screening of the patients' medical history for any surgery or accidents that might have introduced metal to their bodies e.g. cerebral artery aneurysm clips or a metal foreign body in an eye. This will require a review of the patient's notes once consent has been given and a written checklist at the time of MRI scan. Such patients are not scanned in standard clinical practice and would also be excluded from the study.
Therefore, there is no realistic potential for pain, discomfort, distress, inconvenience or detrimental change to lifestyle anticipated for the participants from the MRI scan itself.
- Dillman, J.R., J.H. Ellis, R.H. Cohan, P.J. Strouse, and S.C. Jan, Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol, 2007. 189(6): p. 1533-8.
Unexpected clinical findings
If new abnormalities or medical issues come to light as a result of the study investigations, the patient's GP and hospital consultant will be informed. Medical follow-up of these issues will be through the patient's usual medical carers.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Heart failure | – | –Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years. |
| Control | – | –Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast. |
Who may qualify
- Ages
- Up to 16 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- 1. Heart Failure Patients (MRI Clinically indicated) 2. Heart Failure Patients (Voluntarily recruited from clinic) 1. 8-16 years of age 2. Non-GA only 3. Control subjects (Clinically indicated brain MRI with contrast)
Key inclusion criteria (3 listed)
- Established diagnosis of DCM for 3 months
- Ability to cooperate with MRI scan without general anaesthesia (volunteers over 8 years), or any age if cardiac MRi clinically indicated
- Provides written, informed consent
Key exclusion criteria (19 listed)
- Patient exclusion criteria:
- Estimated GFR <30mls/min
- Contraindication to MRI (see appendix 1)
- Chronic inflammation/ malignancy/ connective tissue disease
- Structural congenital heart disease/ previous cardiac surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Fibrosis
Time frame: 6 months
Higher fibrosis score (ECV) in heart failure patients in comparison to control subjects
2 secondary outcomes
Biomarkers
Time frame: 6 months
Disease Severity
Time frame: 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2022.
Related trials for Dilated Cardiomyopathy
RecruitingPhase 1/2
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy
Active, not recruiting
Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling
Heart Failure, Left Ventricular Dysfunction
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 1/2
Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)
Heart Failure, Ischemic Heart Failure
RecruitingObservational study
Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults
Dilated Cardiomyopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Burch, MD study director
Great Ormond Street Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dilated Cardiomyopathy, run by Great Ormond Street Hospital for Children NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 20 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fibrosis (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2022.